ViroPharma Incorporated (Nasdaq: VPHM) announced that the FDA has granted priority review for Cinryze C1 Inhibitor (human) as a treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE